methyl 3-bromo-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxylate | 943828-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: methyl 3-bromo-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxylate
• CAS: 943828-20-4
• 化学式: C₈H₉BrO₃
• 分子量: 233.062
• InChiKey: YNUUIFHTUFUCMV-UHFFFAOYSA-N

物化性质

• 沸点：
  283.6±40.0 °C(Predicted)
• 密度：
  1.694±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-bromo-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxylate 在 四(三苯基膦)钯 、 sodium carbonate 、 lithium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 6.75h， 生成 3-(6-(trifluoromethyl)pyridin-2-yl)-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxylic acid
  参考文献：
  名称：

  COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS

  摘要：

  本发明提供了I式化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这些化合物的制药组合物，以及使用这些化合物治疗哺乳动物的关节损伤或关节损伤并诱导间充质干细胞分化为软骨细胞的方法。

  公开号：

  US20150329554A1
• 作为产物：
  描述：

  methyl 3-bromo-7-oxabicyclo[2.2.1]hepta-2,5-diene-2-carboxylate 在 palladium on activated charcoal 氢气 作用下， 以 环己烷 为溶剂， 反应 12.0h， 生成 methyl 3-bromo-7-oxabicyclo[2.2.1]hept-2-ene-2-carboxylate
  参考文献：
  名称：

  QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter

  摘要：

  Data from a series of 29 monoamine transport inhibitors were used to generate 2D and 3D QSAR models for their binding affinity to the human dopamine transporter (hDAT). Among the inhibitors were many non-nitrogen containing compounds. The 2D QSAR analysis resulted in the equation -log K-i = 4.00 - 3.93E(LUMO) - 0.67E(HOMO) - 3.24 sigma(p), which predicted the importance of electron withdrawing groups in the aromatic moiety. However, the model failed to predict the observed poor binding of nitro-substituted compounds. In contrast, a derived 3D QSAR model was capable of predicting these more correctly. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.05.015

文献信息

• Compounds and compositions for inducing chondrogenesis
  申请人：NOVARTIS AG

  公开号：US10188638B2

  公开（公告）日：2019-01-29

  The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

  本发明提供了式 I 的化合物： 或其药学上可接受的盐、同系物或立体异构体，其中变量如本文所定义。本发明进一步提供了包含此类化合物的药物组合物，以及使用此类化合物治疗哺乳动物关节损伤或关节损伤和诱导间充质干细胞分化为软骨细胞的方法。
• US9688689B2
  申请人：——

  公开号：US9688689B2

  公开（公告）日：2017-06-27
• [EN] COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS<br/>[FR] COMPOSÉS ET COMPOSITIONS D'INDUCTION DE LA CHONDROGENÈSE
  申请人：NOVARTIS AG

  公开号：WO2015175487A1

  公开（公告）日：2015-11-19

  The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.